Faculty
Faculty Treating MPNs and Systemic Mastocytosis (SM)
At UT MD Anderson, our leading myeloproliferative neoplasm (MPN) physicians have extensive experience and expertise in diagnosing and optimally treating all the MPN subtypes (myelofibrosis, polycythemia vera, essential thrombocythemia), systemic mastocytosis and other myeloid neoplasms.
Drawing upon their advanced expertise and the clinical trials that they lead at UT MD Anderson evaluating novel medications, our MPN physicians design optimal, personalized care plans that aim to improve the quality of life and the outcomes of our patients and provide excellent patient care.
Professor, Co-Section Head of MPNs, Clinical Research Center for MPNs
Leukemia Department
Treats MPN patients
Professor, Co-Section Head of MPNs, Clinical Research Center for MPNs
Director of the BPDCN Program, Leukemia Department
Treats MPN patients
Associate Professor, Leukemia Department
Treats MPN patients
Assistant Professor, Leukemia Department
Treats SM patients
Awards
Myeloproliferative neoplasm team members received the 2020 Waun Ki Hong Award for Excellence in Team Science
Top row (left to right): , and
Bottom row (left to right): , Srdan Verstovsek, M.D., Ph.D., and
This vibrant and prolific MPN Team has led to exceptional advancements in prognosis, diagnosis and treatment of MPN that have significantly improved patient quality of life and survival through collaborative efforts and discovery and combined clinical, morphologic and molecular expertise.